Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes. (July 2016)

• Record Type: Journal Article
• Authors: Qian, Shan; Zhang, Man; He, Yanying; Wang, Wei; Liu, Siyan
• Is Part Of: Future medicinal chemistry. Volume 8:Number 11(2016)
• Page Start: 1239
• Page End: 1258
• Publication Date: 2016-07
• Subjects: insulin resistance -- protein tyrosine phosphatase 1B -- Type 2 diabetes; Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.4155/fmc-2016-0064
• Languages: English
• ISSNs: 1756-8919

Abstract

Diabetes mellitus is the most serious and prevalent metabolic disorders worldwide, complications of which can decrease significantly the quality of life and contribute to premature death. Resistance to insulin is a predominant pathophysiological factor of Type 2 diabetes (T2D). Protein tyrosine phosphatase 1B (PTP1B) is an important negative factor of insulin signal and a potent therapeutic target in T2D patients. This review highlights recent advances (2012–2015) in research related to the role of PTP1B in signal transduction processes implicated in pathophysiology of T2D, and novel PTP1B inhibitors with an emphasis on their chemical structures and modes of action.